abstract |
Protein tyrosine kinase inhibitor compounds are described, as are methods for their preparation, pharmaceutical compositions including such compounds, and their use in medicine, for example in the treatment of cancer and psoriasis. In particular, the use of an inhibitor of both EGFR and erbB-2 in the treatment of a susceptible malignancy, such as cancer or a malignant tumour, is described. |